2012-09-28 16:41:57 - New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope
* Patient-based forecasts for Onyx's lead pipeline candidate, Kyprolis (carfilzomib), supported by key opinion leader research
* Assessment of Onyx's corporate strategy, operating performance, and earlier-stage pipeline

Highlights

In July 2012, the FDA granted accelerated approval for Onyx's proteasome inhibitor Kyprolis for the treatment of patients with multiple myeloma who have received at least two prior therapies including Celgene's Velcade and an immunomodulatory agent and have demonstrated disease progression

on or within 60 days of completion of the last therapy.


Full Report Details at
- www.fastmr.com/prod/464849_onyx_pharmaceuticals_company_analysis ..


Onyx expects to file Kyprolis for approval in the EU in 2013 based on the results of the Phase III ASPIRE trial.

Reasons to Get this Report
* Evaluate the prospects for Onyx's three key products: Kyprolis, Nexavar, and regorafenib
* Assess hematologist-oncologists' views in anticipation of Kyprolis's launch

Report Table of Contents:

ABOUT THIS REPORT

* PharmaVitae Explorer database
* Chapter structure

* Sales and product analysis
* Financial analysis

* Data sourcing

* Analyst consensus
* Primary research

EXECUTIVE SUMMARY

* Company introduction

* Recent developments
* Corporate relationships

* Strategic overview
* SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

SALES AND PRODUCT ANALYSIS

* Sales overview
* Product analysis

* Product sales

* Kyprolis (carfilzomib)

* Multiple myeloma background
* Kyprolis clinical trials
* Factors affecting the use of Kyprolis
* Competitors in late-stage Phase III development

* Nexavar (sorafenib)

* Nexavar in RCC and HCC

* Regorafenib

* Regorafenib in colorectal cancer
* Positive data make approval likely, but uptake may be low
* Regorafenib in gastrointestinal stromal tumor

* Early-stage agents

* PD-332991
* ONX 0914

FINANCIAL ANALYSIS

* Financial performance overview

* Operating costs and profit analysis, 2005-11
* Operating costs and profit analysis, 2011-17

APPENDIX

* Primary research
* References
* Exchange rates

TABLES

* Table: Onyx pipeline
* Table: Onyx product portfolio overview ($m), 2011-17
* Table: Summary of efficacy results from the Phase II 003-A1 trial
* Table: Summary of efficacy results from the Phase I/ll Kyprolis front-line trial
* Table: Selected Kyprolis trials in multiple myeloma
* Table: Incidence of peripheral neuropathy in clinical trials
* Table: Multiple myeloma drugs in Phase III trials
* Table: Summary of efficacy results from the Phase I/ll MM-002 pomalidomide trial
* Table: Kyprolis sales forecast, 2012-17
* Table: Nexavar sales forecast ($m), 2011-17
* Table: Summary of efficacy results from the Phase III CORRECT trial
* Table: Regorafenib sales forecast ($m), 2011-17
* Table: Onyx operating revenue/cost analysis ($m), 2005-11
* Table: Onyx operating revenue/cost analysis ($m), 2011-17
* Table: Exchange rates, 2012

FIGURES

* Figure: PharmaVitae Explorer
* Figure: Onyx prescription pharmaceutical performance, sales ($m) and growth rate 2011-17
* Figure: Onyx product sales ($m), 2011-17
* Figure: Onyx operating revenue/cost analysis ($m), 2005-17

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.